Gold
EW3B: Sep. 24 (Thu), 18:30-19:30/ Room B (2F)
| Address | 416, Hangang-daero, Jung-gu, Seoul, Korea | ||
|---|---|---|---|
| Telephone | +82-2-331-2000 | Fax | |
| Website | https://www.msd-korea.com/ | dpoc_korea@merck.com | |
We are a global healthcare company with a 125-year history of working to make a difference.
• OUR HISTORY : Our rich history of discovery and innovation began more than 125 years ago and continues today. Through the years, our researchers have helped to find new ways to treat and prevent illness in people and animals around the world. We've done great things in the past. Today, we're doing great things for the future.
• OUR PAST, OUR FUTURE : In 2016, MSD celebrated its 125th anniversary as a global health care leader. Learn more about our accomplishments as well as what we're excited about for the years to come.
• OUR RESEARCH : We are determined to transform breakthrough science into novel therapeutic and vaccine options. Curiosity, inventiveness and a passion for excellence are what drive our people to discover what's possible.
- MAIN PRODUCTS : KEYTRUDA, GADASIL, JANUVIA, PROPECIA, SINGULAIR
KEYTRUDA is an immunotherapeutic anti-cancer drug for NSCLC, Urothelial, HNSCC, Endometrial, Gastric, Colorectal cancer, Small intestine, Ovarian, Pancreatic, Biliary cancers, Melanoma and classical Hodgkin Lymphoma in Korea.
It is also an KFDA approved CDx drug, which engages IHC (PD-L1, EBV, MMR etc), PCR(MSI-H), NGS tests guidelines.
It works with human immune system to help fight those cancers.
Countless patients are getting new lives again from that.
KEYTRUDA is the number 1 in sales among all drugs in the world & in Korea.
